Zajaczkowski J, Pituch A, Kolanowska H, Michalik R
Folia Haematol Int Mag Klin Morphol Blutforsch. 1975;102(4):403-9.
Nineteen children aged from 3 to 16 years with first long-term hematologic remission were studied. Cell-mediated immunity was assayed by the reaction to dinitrochlorobenzene (DNCB), nitroblue tetrazolium reduction test (NBT) and lysozyme activity. Humoral immunity was determined by immunoglobulin (IgG, IgA, IgM) levels in serum. The DNCB-reaction was positive in 50% of children treated from 12 to 36 months. Percentage and absolute counts of NBT-positive granulocytes and lysozyme/granulocyte ratio systematically increased with time of therapy. In all studied children IgG was normal, IgA and IgM were depressed to 40% and 76% of normal value (with the exception of 2 children after cessation of therapy, in which IgA was normal). It seemed that continuous control of the immunologic status during long-term cytostatic therapy is essential in clinical practice.
对19名年龄在3至16岁且首次长期血液学缓解的儿童进行了研究。通过二硝基氯苯(DNCB)反应、硝基蓝四氮唑还原试验(NBT)和溶菌酶活性来检测细胞介导免疫。通过血清中免疫球蛋白(IgG、IgA、IgM)水平来测定体液免疫。在接受治疗12至36个月的儿童中,50%的儿童DNCB反应呈阳性。NBT阳性粒细胞的百分比和绝对计数以及溶菌酶/粒细胞比值随治疗时间系统性增加。在所有研究儿童中,IgG正常,IgA和IgM分别降至正常值的40%和76%(治疗停止后有2名儿童除外,其IgA正常)。在临床实践中,长期细胞抑制治疗期间持续监测免疫状态似乎至关重要。